Intelligent Investor
Sign up for free Sign up for free Sign up for free

Integral Diagnostics Limited (ASX: IDX) - Share Price and Research

- Current share price for IDX : $2.720

Integral Diagnostics Limited (IDX), an ASX-listed company, is a provider of medical imaging services across Australia and New Zealand. It employs Australasia's radiologists and diagnostic imaging specialists in a medical leadership model that ensures patient care, service and access.

IDX General Information +

ASX Code IDX
Website http://www.integraldiagnostics.com.au
Industry/Sector Health Care Services
Market Cap ($M) 1,013
IDX Share Price $2.720
Day High $2.720
Day Low $2.660
Last Close $2.720
IDX Share Price Movement - ( No change )
Prices as at 16:40, 29 Jul 2025
+Security prices are delayed by at least 20 minutes and are indicative only.

Recommendation

Integral Diagnostics Limited - IDX
Current price
$2.72 at 16:40 (29 July 2025)

Price at review
$2.60 at (16 September 2024)

Max Portfolio Weighting
Maximum Portfolio Weighting Locked

Business Risk
Business Risk Locked

Share Price Risk
Share Price Risk Locked
All Prices are in AUD ($)
Upsell Banner

IDX Related Research

Integral Diagnostics Limited (IDX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Result 2.5¢ 100% 6 Mar 2025 7 Apr 2025 $2.720 $2.680 2.13%
HFResult 3.3¢ 100% 30 Aug 2024 3 Oct 2024 $2.720 $2.680 2.13%
Result 2.5¢ 100% 29 Feb 2024 2 Apr 2024 $2.720 $2.680 2.13%

See all dividends from Integral Diagnostics Limited (IDX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Integral Diagnostics Limited (IDX) price-sensitive announcements

IDX - Commencement of litigation
Integral Diagnostics Limited (IDX) announced the commencement of litigation regarding a di
Integral Diagnostics Limited (IDX)
23 Jul 2025 | 9:36 AM
IDX - Retirement of Managing Director and Chief Executive Officer
Integral Diagnostics Limited (IDX) has announced the planned retirement of Dr. Ian Kadish
Integral Diagnostics Limited (IDX)
6 Jun 2025 | 4:12 PM
IDX - FY25 Half Year Results Investor Presentation
Integral Diagnostics Limited reported strong financial results for the first half of FY25,
Integral Diagnostics Limited (IDX)
26 Feb 2025 | 8:34 AM
IDX - FY25 Half Year Results Media Release
Integral Diagnostics Limited (IDX) has announced its financial results for the half year e
Integral Diagnostics Limited (IDX)
26 Feb 2025 | 8:16 AM

See more price-sensitive ASX announcements or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

Integral Diagnostics Limited (IDX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Integral Diagnostics Limited (IDX)
ORDINARY FULLY PAID
Health Care $1,013 IDX FY25 Results Conference Call 23 Jul 2025 9:37AM $2.770 $2.720 fallen by 1.81%
Integral Diagnostics Limited (IDX)
ORDINARY FULLY PAID
Health Care $1,013 Commencement of litigation 23 Jul 2025 9:36AM $2.770 $2.720 fallen by 1.81%
Integral Diagnostics Limited (IDX)
ORDINARY FULLY PAID
Health Care $1,013 Ceasing to be a substantial holder 26 Jun 2025 8:22AM $2.410 $2.720 risen by 12.86%
Integral Diagnostics Limited (IDX)
ORDINARY FULLY PAID
Health Care $1,013 Release of Ordinary Shares from Escrow 19 Jun 2025 6:05PM $2.260 $2.720 risen by 20.35%
Integral Diagnostics Limited (IDX)
ORDINARY FULLY PAID
Health Care $1,013 Retirement of Managing Director and Chief Executive Officer 6 Jun 2025 4:12PM $2.320 $2.720 risen by 17.24%
Integral Diagnostics Limited (IDX)
ORDINARY FULLY PAID
Health Care $1,013 Notification of cessation of securities - IDX 4 Jun 2025 6:10PM $2.390 $2.720 risen by 13.81%

IDX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026F $59.29 $15.80 79.80% 18.67 12.00 4.07% 100.0%
2025F $32.98 $8.79 -4.30% 33.56 6.50 2.20% 100.0%
2024A $21.70 $9.18 31.10% 26.67 5.80 2.37% 100.0%

IDX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 F 2026 F 2024 A 2025 F 2026 F 2024 A 2025 F 2026 F
Australian Clinical Labs Limited (ACL) $556M 0.2216 -0.0560 0.1538 15.1014 15.9977 13.8658 4.24% 4.06% 4.77%
Healius Limited (HLS) $581M -0.8459 0.0000 0.0000 60.1504 0.0000 727.2727 0.00% 51.44% 0.44%
Integral Diagnostics Limited (IDX) $1,024M -4.6612 0.0000 0.9943 0.0000 39.0625 19.5869 2.11% 2.00% 3.82%
Sonic Healthcare Limited (SHL) $13,873M -0.3074 -0.0110 0.2851 27.9526 28.2622 21.9915 3.78% 3.85% 4.17%

IDX Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 38.60 2.11 0.64
Market 0.24 13.90 1.11 0.73
Sector 0.79 31.60 1.88 2.70

IDX Directors

Name Position Start Date
Dr Ian Kadish Chief Executive Officer, Managing Director 22 May 2017
Mr Andrew James Fay Non-Executive Director 18 Jul 2022
Ms Raelene Margaret Murphy Non-Executive Director 1 Oct 2017
Ms Ingrid Anne Player Non-Executive Director 29 Aug 2023
Ms Laura Nicole McBain Non-Executive Director 20 Dec 2024
Dr Kevin (Kai-Chung) Shaw Non-Executive Director 20 Dec 2024
Mr Manish Mittal Non-Executive Director 5 Feb 2025
Mr James Tobias Hall Non-Executive Director, Non-Executive Chairman 28 Sep 2023

Integral Diagnostics Limited (IDX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
7 Apr 2025 HALL, James Issued Indirect Shares 2,088 $2.270 $4,738.948
11 Mar 2025 MURPHY, Raelene Buy Indirect Shares 15,000 $2.360 $35,400.000
5 Mar 2025 KADISH, Ian Buy Direct Shares 25,000 $2.158 $53,950.000

See all changes in directors' interest & trades for Integral Diagnostics Limited (IDX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IDX Management

Name Position
Craig White Chief Financial Officer
John J Merity Company Secretary

IDX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Integral Diagnostics Limited (IDX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
20,362,716 (8.72%) Yarra Funds Management Limited
16,105,036 (6.88%) Viburnum Funds Pty Ltd
13,470,639 (5.77%) Integral Diagnostics Limited

IDX Calendar of Events

Date Event
25 February 2026 Report (Interim)
26 August 2025 Report (Annual)
26 August 2025 Report (Prelim)

FAQs about Integral Diagnostics Limited (IDX)

Integral Diagnostics Limited's (IDX) current share price is $2.72. This constitutes a price movement of 1.49% when compared to the share price 7 days ago and is -14.20% below IDX's 12-month high of $3.17 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $2.72, Integral Diagnostics Limited's (IDX) current share price of $2.72 constitutes a movement of or 0%. Integral Diagnostics Limited's (IDX) share price movement is 1.49% when compared to 7 days ago and is -14.20% below IDX's 52-week high of $3.17.

Integral Diagnostics Limited's (IDX) 52-week high is $3.17 which was reached on 22 Oct 2024. Relative to this, IDX's current share price of $2.72 constitutes a -$0.45 or -14.20% drop since that high of $3.17 per IDX share.

Integral Diagnostics Limited's (IDX) 52-week low is $2.13 which was reached on 28 Feb 2025. Relative to this, IDX's current share price of $2.72 constitutes a $0.59 or 27.70% gain since that low of $2.13 per IDX share.

Over the last 12 months, Integral Diagnostics Limited (IDX) has a daily average trading volume of 1,076,780 IDX shares per day.

Integral Diagnostics Limited (IDX) has a current dividend yield of n/a this year. Last year's dividend yield was 2.20%. The dividend yield for IDX is a ratio that tells you the percentage of Integral Diagnostics Limited's (IDX) share price that it pays out in dividends each year.

Integral Diagnostics Limited (IDX) last dividend payment was $0.03 per share and was paid on 7 Apr 2025. This last IDX dividend included 100% franking.

Integral Diagnostics Limited (IDX) has a franking level of 100%. Franking represents the tax Integral Diagnostics Limited (IDX) has already paid on any profit it distributes to shareholders as a dividend.

Integral Diagnostics Limited (IDX) will release its next Annual Report on 26 August 2025. Integral Diagnostics Limited's (IDX) last annual report was released on 27 Aug 2024. Click here to view Integral Diagnostics Limited's (IDX) last annual report.

Integral Diagnostics Limited (IDX) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Pro Medicus Limited (PME), and Sigma Healthcare Limited (SIG).

The price-to-earnings (P/E) ratio for Integral Diagnostics Limited (IDX) is 38.6. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Integral Diagnostics Limited's (IDX) share price to its earnings per IDX share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.